SPRAVATO - Johnson & Johnson
5 days ago · Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental …
FDA approves standalone use of J&J’s ketamine-derived ... - CNN
5 days ago · The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe …
FDA approves Johnson & Johnson nasal spray Spravato for …
5 days ago · Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
Janssen Announces U.S. FDA Approval of SPRAVATO - Johnson & Johnson
Aug 3, 2020 · SPRAVATO ® is approved in the United States, in conjunction with an oral antidepressant, to treat adults with treatment-resistant depression (TRD) and depressive …
SPRAVATO® (esketamine): A Prescription Nasal Spray | SPRAVATO…
You may report side effects to Johnson & Johnson at 1-800-526-7736, or to the FDA at 1-800-FDA-1088. Please see full Prescribing Information , including Boxed WARNINGS, and …
SPRAVATO® (esketamine) approved in the U.S. as the first and …
6 days ago · Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for …
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® …
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
FDA Approves Johnson & Johnson’s Spravato for Treatment …
6 days ago · The FDA has approved Johnson & Johnson’s (J&J) Spravato (esketamine) CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant …
FDA approves first-of-its-kind nasal spray for severe depression
5 days ago · At the end of week four of the trial, just 7.6-percent of the placebo group reported a MADRS score indicating remission, compared to 22.5-percent of those taking Spravato. …
FDA allows standalone use of nasal spray antidepressant Spravato ...
5 days ago · The decision came after a large study found that Spravato alone worked better than a placebo. In the first nine months of 2024, the drug generated sales of about $780 million for …